# Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

> **NCT05065021** · PHASE2 · UNKNOWN · sponsor: **University Health Network, Toronto** · enrollment: 40 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- High Grade Serous Cancer
- High Grade Endometrioid Cancer

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Dostarlimab
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05065021
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-23
- **Primary completion:** 2025-06-06
- **Final completion:** 2025-06-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05065021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05065021, "Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05065021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*